Abbot Financial Management, Inc. Rubius Therapeutics, Inc. Transaction History

Abbot Financial Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $439,760 - $1.23 Million	-956,000 Reduced 67.88%	452,345 $196,000
Q1 2022 May 12, 2022	SELL	$4.25 - $10.4 $11,305 - $27,664	-2,660 Reduced 0.19%	1,408,345 $7.76 Million
Q4 2021 Feb 15, 2022	SELL	$9.68 - $17.74 $7,453 - $13,659	-770 Reduced 0.05%	1,411,005 $13.7 Million
Q2 2021 Aug 05, 2021	SELL	$22.26 - $28.43 $60,658 - $77,471	-2,725 Reduced 0.19%	1,411,775 $34.5 Million
Q1 2021 May 13, 2021	BUY	$8.02 - $32.01 $7.04 Million - $28.1 Million	877,500 Added 163.41%	1,414,500 $37.5 Million
Q4 2020 Feb 11, 2021	SELL	$4.23 - $8.73 $112,095 - $231,345	-26,500 Reduced 4.7%	537,000 $4.08 Million
Q4 2019 Feb 12, 2020	BUY	$7.23 - $14.12 $4.07 Million - $7.96 Million	563,500 New	563,500 $5.35 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Abbot Financial Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Abbot Financial Management, Inc. with notifications on news.